

Pediatric Glioma at the Optic Pathway and Thalamus

Eun Suk Park, M.D.,¹ Jun Bum Park, M.D.,¹ Young-Shin Ra, M.D.²

*Department of Neurosurgery,¹ Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
Department of Neurological Surgery,² Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*

Gliomas are the most common pediatric tumors of the central nervous system. In this review, we discuss the clinical features, treatment paradigms, and evolving concepts related to two types of pediatric gliomas affecting two main locations: the optic pathway and thalamus. In particular, we discuss recently revised pathologic classification, which adopting molecular parameter. We believe that our review contribute to the readers' better understanding of pediatric glioma because pediatric glioma differs in many ways from adult glioma according to the newest advances in molecular characterization of this tumor. A better understanding of current and evolving issues in pediatric glioma is needed to ensure effective management decision.

Key Words : Pediatrics · Brain neoplasms · Optic tract · Thalamus · Therapeutics · Treatment outcome.

INTRODUCTION

Gliomas are the most common central nervous system (CNS) tumors affecting pediatric patients⁶⁰. These tumors exhibit an extremely broad range of clinical behaviors. Their clinical features and courses can be affected by various factors, particularly location and pathology. The site of origin of a pediatric glioma within the CNS⁶⁰ can influence both the clinical presentation and the selection of surgical management. Various pathological subgroups of pediatric glioma, ranging from indolent (e.g., pilocytic astrocytoma) to aggressive tumors (e.g., glioblastoma), have been identified. The pathological characteristics of these subgroups should be considered during tumor management.

In the last decade, significant progress has been made in our understanding of the molecular biology underlying pediatric gliomas^{11,42,81}. Notably, biologic subgroups characterized by dis-

tinct molecular, pathologic, and clinical features have been identified, with the 2016 World Health Organization classification of tumors of the CNS adopting this concept⁵⁵. In this review, we summarize the literature regarding pediatric gliomas located in the supratentorial deep midline in terms of both current concepts and evolving issues. We particularly focus on two main locations, the optic pathway and thalamus. Accordingly, our review is constructed around the two main themes of gliomas occurring in these locations.

OPTIC PATHWAY GLIOMAS

Clinical features

Optic pathway gliomas (OPGs) account for approximately 3–5% of pediatric brain tumors^{8,72}. Approximately 75% of these

• Received : February 14, 2018 • Revised : March 15, 2018 • Accepted : March 29, 2018

• Address for reprints : **Young-Shin Ra, M.D.**

Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel : +82-2-3010-3550, Fax : +82-2-476-6738, E-mail : ysra@amc.seoul.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

tumors are diagnosed during the first decade of life, with 60% of patients receiving a diagnosis before the age of 5 years; the incidence does not differ by sex^{8,26}. OPGs can affect several anatomic regions along the optic pathway. The size and extent of the tumor influences the presentation, ranging from pure optic pathway gliomas (which are located in the optic nerve, optic chiasm, optic tracts and, less frequently, optic radiation) to larger exophytic tumors with extension into the hypothalamus, pituitary gland, third ventricle, and diencephalon^{8,26}. Overall, 25% of OPGs are confined to the optic disc and nerve, whereas 40–75% involve the chiasm; of the latter, 33–60% are considered posterior lesions and also involve the hypothalamus or third ventricle⁸.

Patients with OPGs may be asymptomatic or may present with variable symptoms, depending on the tumor location. The presenting symptoms are mainly ophthalmologic, including decreased or loss of vision, proptosis, strabismus, and nystagmus; these symptoms are often caused by a compromise of the optic pathways or diencephalon by either direct tumor invasion or compression^{4,26,36}. Non-ophthalmologic symptoms may include endocrine dysfunction, cognitive problems, and behavioral disturbances^{4,26}. Endocrinologic symptoms such as precocious puberty and diencephalic syndrome indicate that an OPG affects the midline hypothalamic structures⁷². Symptoms of increased intracranial pressure (ICP) with hydrocephalus may also occur if the tumor obstructs the flow of cerebrospinal fluid through the third ventricle²⁶.

Incidentally discovered OPGs are typically associated with neurofibromatosis type 1 (NF-1). The reported incidence of NF-1 among patients with OPGs varies from 10 to 70%; a majority of patients with these lesions are thought to have NF-1^{26,67,72}. OPGs associated with NF-1 are more often benign, may be multifocal and bilateral, and are usually found within the optic nerve^{31,45,82}. Notably, the presence of bilateral OPGs is a pathognomonic feature of NF-1 and was identified in 34.8% of patients with the condition. Chiasmatic glioma is rarely associated with NF-1; however, such tumors often have a more aggressive course with diencephalic syndrome, and typically progress^{31,45,82}.

Before making treatment decisions, as much information as possible must be obtained from imaging evaluations. The diagnoses of OPGs with typical imaging appearances can be confirmed using modern imaging modalities and protocols^{8,26}. Radiologic evaluations of the tumor and surrounding struc-

tures play a critical role in pre-surgical planning. Although both computed tomography and magnetic resonance imaging (MRI) are useful for radiologic evaluations, the latter is considered the mainstay of diagnostic imaging for pediatric OPGs²⁶. In such cases, typical MRI findings include the appearance of an iso- to hypointense lesion on T1-weighted images, hyperintensity on T2-weighted images, and homogeneous enhancement with Gd administration^{8,78}. These tumors are normally solid but may have cystic components; however, they rarely exhibit leptomeningeal spread, which tends to occur with more aggressive tumors such as pilomyxoid astrocytomas^{26,44,55}. Therefore, imaging can be used for tumor classification. Several researchers invented radiological classification using OPGs' anatomic location and their relation to the optic pathways²¹. A recent report further proposed an MRI interpretation protocol intended to reduce intraobserver discrepancies⁴⁷. We note, however, that prognostic validation is needed for classifications based solely on radiologic features, as these do not address surgical, genetic, and pathological factors.

Recently, newer MR imaging techniques such as MR spectroscopy (MRS), perfusion and diffusion-weighted MRI, and diffusion tensor imaging have been used for the pre- and post-treatment evaluation of OPGs. Reports have described the use of the former two techniques for tumor grading^{71,87}, whereas the latter has been used to assess the integrity of white matter tracts, including the optic radiations^{72,76}.

Management

Pathologically, OPGs are generally considered low grade^{8,26}. Juvenile pilocytic astrocytoma is the predominant histology and high-grade malignant pediatric OPGs are infrequently observed. Although clinical course predictions are difficult, as the natural courses range from stable disease to progression and even spontaneous regression^{34,59,65,76}. However, a large proportion of OPGs exhibit an indolent nature, particularly in the context of NF-1⁵⁹. Still, tumor progression is typically observable within 2 years of diagnosis⁸³. Despite the rarity of progression after the age of 12 years, some patients may lose their vision in adolescence. Therefore, these children should be subjected to careful vision monitoring until they reach adulthood.

Currently, the management options for OPGs include followed observation, chemotherapy, radiation therapy, and surgery. Given the pathologic and genetic diversity of OPGs, good long-term survival and functional results require a multidisci-

plinary approach. Careful observation and timed intervention may be appropriate and reasonable options for these generally indolent tumors, particularly in the context of NF-1. However, patients presenting with symptoms and/or tumor progression on serial imaging scans should be considered candidates for appropriately selected interventions.

Because a significant portion of patients with OPGs also have NF-1, we consider it important to discuss the current recommendations for the screening of this population of patients. In 1997, the NIH NF-1 Optic Glioma Task Force outlined recommendations for the screening, follow-up, and treatment of OPG in children with NF-1⁵³; Listernick et al.⁵² updated these initial recommendations in 2007. The updated recommendations strongly emphasize an annual screening examination, including visual acuity testing, confrontation visual field testing, color vision, pupillary reflexes, and an assessment of eyelids, ocular motility, and fundi, for children up to 8 years of age. Although no agreement has been reached regarding the time interval for the screening of patients older than 8 years, the guidelines recommend biennial screening until the age of 18 years until proven otherwise. Furthermore, the guidelines do not recommend using visual evoked potential as a screening tool. Regular ophthalmological examinations of NF-1 children with a known OPG at 3-month intervals are recommended during the first year, with larger intervals thereafter if progression is not evident.

OPGs require an individualized treatment approach based on combinations of surgery, chemotherapy, and/or radiotherapy. Accordingly, management decisions should be made through multidisciplinary team discussion after weighing the pros and cons of each treatment. For many years, the treatment of choice for OPG was surgical excision, which provided either a cure or prolonged stability^{32,84}. However, in some cases, such as NF-1 patients, it is discouraged because it inevitably causes blindness on the affected side, with the risk of bilateral loss of vision⁴⁹. Furthermore, surgical biopsy has been supplanted by imaging-assisted virtual diagnosis. Therefore, surgery should only be used in specific circumstances, such as the treatment of lesions causing significant unilateral visual compromise (often blindness) with evidence of extension into the chiasm, which thus threatens vision in the other eye. Here, prechiasmatic transection of the optic nerve can prevent tumor progression toward the chiasm, thereby maintaining vision in the contralateral eye⁹. In such cases, thorough clinical and radiologic testing should be used to ensure that there is no involvement of the chiasm prior

to surgical intervention. Other circumstances, including painful proptosis, corneal exposure, and disfigurement with severe visual loss in the involved eye, may also warrant surgical intervention^{49,52,72}. Additionally, significant OPG growth can compress the third ventricle and thus cause hydrocephalus, necessitating lesion debulking to prevent further neurologic compromise^{4,26}.

Chemotherapy has become the predominant treatment modality for OPGs. Previously, this option was recommended as a first-line treatment for children under 7 years of age. Older children were initially offered radiotherapy⁸, as chemotherapy was shown to delay the need for radiotherapy in young children and thus allow time for neuropsychological development. However, the avoidance of radiation toxicity has led to the emergence of chemotherapy as the preferred first-line treatment, regardless of age, since 2000^{36,54}. Chemotherapy may stabilize or reduce the disease burden and thus prevent the need for neurosurgery and radiotherapy^{26,36,57}. Although no single ideal chemotherapeutic agent has been identified, the current standard chemotherapy regimen of vincristine and carboplatin, commonly known as the Packer regimen^{62,63}, was reported by Packer and colleagues to yield progression-free survival rates of 75% at 2 years and 68% at 3 years⁶². Alternative chemotherapeutic regimens including thioguanine, procarbazine, lomustine, and vincristine with or without dibromodulcitol have yielded efficacies similar to that of the classical carboplatin and vincristine regimen^{3,68}. Temozolomide has also been shown to stabilize disease in more than 50% of patients without significant toxicity, and is considered an option for patients with progressive OPG in whom first-line therapy has failed³³. Additionally, a recent report described improved visual function in select patients treated with bevacizumab⁵. A systematic review of the effects of chemotherapy on visual outcomes found that less than 15% of cases demonstrated improvement, while 40% exhibited deterioration. Overall, the investigators concluded that chemotherapy did not improve the visual outcomes of children with OPGs⁵⁸. However, among NF-1 patients treated with chemotherapy, visual acuity remained stable or improved in 72% of patients and declined in 28%²⁴. Researchers have also highlighted the importance of earlier treatment (i.e., treatment initiation <5 months from diagnosis) to prevent the occurrence of irreversible vision damage^{2,24}.

The role of radiotherapy in OPGs has changed considerably over the past decade. It used to be the treatment of choice, ahead of chemotherapy¹⁵. Radiotherapy is an effective treatment for

OPGs, with reported 10-year rates of progression-free survival as high as 90%⁸⁰. Conventional external beam radiotherapy for OPG is most commonly administered at total doses of 45–60 Gy in 1.6–2.0 Gy fractions^{27,80}. However, its use has been limited by significant risks, including neuroendocrine dysfunction, and neurodevelopmental delays^{27,33}. Patients with NF-1 are particularly at risk of secondary neoplasms following radiation⁷⁷. Radiation damage also increases the risks of a secondary exacerbation of visual loss, Moyamoya syndrome, and cerebro-occlusive disease²⁸. Approximately 3.5% of all children receiving radiation therapy will develop Moyamoya syndrome; patients with NF-1 have a much higher risk of this condition, compared to the general population²⁰. Therefore, radiotherapy is now reserved for tumors refractory to chemotherapy and surgery.

Fractionated stereotactic radiotherapy, proton beam radiotherapy, and stereotactic radiosurgery have been evaluated as means of reducing the adverse effects of conventional radiotherapy. The former is highly efficacious, with a progression-free survival rate of 72% at 5 years¹⁸. Proton and photon beam therapy, which administer lower doses of radiation to the temporal lobes and pituitary gland, have been tested in small series of patients with promising results⁵¹. Finally, Gamma knife radiosurgery (single session) has been used to treat optic pathway and hypothalamic gliomas; in a recent case series, this modality yielded a progression-free survival rate of 83% at 3 years, and more than 80% of patients experienced stabilized or improved visual acuity²². Despite the efficacies of these new radiotherapy modalities, physicians should remain cautious about the potential for serious adverse effects.

THALAMIC GLIOMAS

Clinical features

Although thalamic gliomas are rare, accounting for 1–5% of pediatric intracranial tumors^{37,46,79}, the incidence of thalamic glioma is relatively high in children relative to adults (1%)³⁷. Pediatric patients are affected at a median age of 8–10 years, without sex predilection^{29,37,79}. The duration of symptoms varies in children, although the mean value of 6 months³⁷ is longer than that in adults. However, a shorter symptom duration may portend a worse prognosis and may correspond to a higher pathologic grade.

Children with thalamic gliomas may present with a range of

symptoms attributable to the deep locations of these tumors^{37,70}. The most common symptoms include an increased ICP, headache, lethargy, nausea, vomiting and, if left untreated, stupor and coma. Visual symptoms are present in as many as 50% of cases. Motor deficits are common, whereas sensory disturbances and movement disorders are less common. In addition to the deep location, tumor effects on the structures surrounding the thalamus may lead to several symptom complexes. For example, hypothalamic involvement results in endocrinopathies, whereas mammillothalamic tract or fornix involvement can cause cognitive dysfunction and memory problems. Additionally, bilateral thalamic lesions manifest the characteristic but unusual presentation of personality changes, memory loss, confusion, hallucinations, hyperphagia, and bradyphrenia³⁷.

Thalamic gliomas can be categorized by growth characteristics as focal, diffuse, or bilateral³⁷. Focal tumors occur at very discrete locations within the thalamus and grow to expand beyond the anatomical boundaries into the surrounding white matter and/or ventricles (third and lateral). These tumors typically correspond to World Health Organization (WHO) grade I juvenile pilocytic astrocytoma¹², and can be further subclassified according to the brain-tumor interface or a cystic or non-cystic component. In contrast, the diffuse type does not display a well-demarcated tumor interface and thus typically migrates beyond its anatomical boundaries. These tumors typically correspond to the WHO grade II–IV fibrillary type¹³.

Bilateral-type thalamic gliomas merit a separate discussion. These tumors, which have an approximate incidence of 14%, are presumed to have a de novo bilateral origin, like multifocal gliomas, and exhibit bilateral symmetry at the time of diagnosis⁷⁹. As in other reports, patients with bilateral thalamic glioma had a relatively shorter mean duration of symptoms (2.5 vs. 8.7 months for unilateral thalamic gliomas)⁷⁹. Surprisingly, although biopsies of these lesions have indicated a lower histologic grade, the prognosis is much worse; in other words, these tumors have a malignant course despite the lower-grade histology^{37,79}.

Radiologic features provide significant clues about the histology of and management options for thalamic gliomas. Advanced neuroimaging provides additional information about the metabolism and physiology of these lesions and thus contributes to diagnosis and follow-up^{10,46}. Similar to the clinical presentations, the imaging characteristics of these tumors vary depending on the grade of malignancy. Up to 20% of tumors are solid and cystic with calcification¹⁰. Furthermore, although

most malignant gliomas exhibit peritumoral edema, enhancement, and necrosis, these characteristics may be absent from some high-grade tumors, which may reduce the reliability of tumor classification and grading based on conventional imaging⁶⁴. Advanced MRI techniques, such as perfusion MRI and MRS, can provide additional information to support tumor classification. On perfusion MRI, low-grade tumors have a relatively low regional cerebral blood volume, compared to high-grade tumors⁵⁶. On MRS, high-grade tumors such as glioblastoma exhibit a high choline peak with a low N-acetylaspartate peak and high choline-to-creatine ratios. Additionally, elevated levels of lipid and lactate, which correlate with necrosis, help to differentiate glioblastomas from high-grade gliomas such as anaplastic astrocytoma¹⁰.

Management

The treatment regimen for pediatric thalamic glioma has not been clearly defined. Clinicians previously favored a conservative approach comprising stereotactic biopsy and radiotherapy over radical resection, given the risks of postoperative morbidity and mortality^{16,25}. However, recent improvements in imaging modalities, neuronavigation systems, microsurgical techniques, and intraoperative electrophysiological monitoring have yielded clear anatomical pictures of these deeply seated lesions; therefore, radical resection of a selected subset of these tumors is associated with minimal morbidity and mortality^{14,37,50,74}. Generally, patients who have undergone total or subtotal resections of thalamic tumors experience improved outcomes and survival prognoses compared to those who do not undergo surgery⁸⁵. Improved overall survival is associated with the extent of resection and can be achieved with minimal occurrences of morbidity and mortality⁸⁵.

Contrast-enhancing discrete lesions with well-defined boundaries and no involvement of the posterior limb of the internal capsule are best suited for radical resection⁷⁴. Various surgical approaches have been described for thalamic gliomas^{37,74,79}, although the position of the internal capsule relative to the tumor is a key factor when determining the approach. The optimal approach typically depends on the location of the tumor within the thalamus and the extent and relationship of the tumor to critical structures⁷⁹. Bilginer et al.⁷ favor the anterior interhemispheric transcallosal approach for superior thalamic tumors and the posterior interhemispheric parasplenial approach for posterior thalamic tumors. Ozek and Türe⁶¹ also recom-

mend the interhemispheric transcallosal approach for patients with superior and anterior thalamic tumors. In contrast, Baroncini et al.⁶ prefer the transcortical frontal approach for tumors in the superior thalamus. For large tumors in highly functional areas or areas with poorly defined boundaries, Puget et al.⁷⁰ recommend the staged excision of thalamic tumors. Tumors that cannot be resected safely should be investigated using biopsy sampling to exclude non-neoplastic pathological entities and direct future adjuvant therapies based on histological tumor types. Stereotactic or endoscopic biopsy should be considered in cases that may require only a tissue diagnosis or are otherwise appropriate (e.g., bilateral thalamic tumors)³⁷. For unilateral lesions with diagnostically ambiguous imaging findings, an imaging or endoscopically guided biopsy can establish a diagnosis and allow the identification of molecular markers before initiating an open approach³⁷.

Radiotherapy and chemotherapy should be reserved for patients with malignant thalamic lesions, multiple recurrent tumors, or residual disease³⁷. However, neither option is superior to complete resection, and both carry potential long-term adverse effects that are of significant concern in young children. Therefore, adjuvant therapies should not be considered without a histological diagnosis³⁷. For incompletely resected or progressive lesions, most centers administer a total radiation dose of 54 Gy administered over 30 fractions^{35,37,66}. However, many centers are switching to primary chemotherapy to avoid late irradiation effects such as endocrinopathies, vasculopathies, optic nerve damage, and loss of intellectual function. Therefore, reoperation should be offered, if feasible, to address a small residual, recurrent, or regrown low-grade glioma on serial imaging.

Currently, no standardized protocol exists for the chemotherapeutic treatment of low-grade gliomas. Generally, these lesions are treated with a combination of agents, although studies have reported varying levels of success with single agents³⁵. However, a combination of vincristine and carboplatin and vinblastine monotherapy have been accepted as first-line adjuvant chemotherapy regimens³⁵. In contrast, the standard treatment for high-grade gliomas comprises surgery followed by radiotherapy. Although various combinations of chemotherapeutic agents have been tested, adult studies have led most pediatric neuro-oncology groups to adopt the combination of radiotherapy with concomitant and adjuvant temozolomide as the standard of care^{23,35}.

The factors influencing survival among patients with tha-

lamic glioma include the tumor grade, extent of resection, adjuvant therapy, and symptom duration^{7,46,79}. Although children with low-grade gliomas have relatively good overall survival rates, the thalamic location portends a worse outcome, despite otherwise similar tumor biology^{37,85}. For high-grade gliomas, radical surgical resection remains the most important prognostic factor and should be considered unless severe morbidity is anticipated^{14,74,85}. Given their location, bilateral thalamic tumors are considered inoperable beyond diagnostic biopsy⁷⁹, and have been reported to be less responsive to radiotherapy and chemotherapy treatment relative to unithalamic tumors^{37,79}. Consequently, bilateral thalamic tumors are associated with a poor outcome.

CONTROVERSIAL AND EVOLVING ISSUES

Several currently evolving issues in this field are notable. First, the 2016 World Health Organization Classification of Tumors of the CNS (Table 1) includes molecular parameters, as well as histology, in the definitions of CNS tumor entities⁵⁵. This represents a significant break from the paradigm of the past century, wherein brain tumor classification was based largely on the concept of histogenesis; that is, tumors can be classified according to their microscopic similarities to different putative cells of origin and their presumed levels of differentiation⁵⁵. Studies conducted over the past two decades have clarified the genetic basis of tumorigenesis in brain tumor entities, raising

Table. 1 The 2016 WHO classification with grade and ICD-O code in pediatric gliomas⁴⁹

Tumor class	Grade	ICD-O code
Diffuse astrocytoma and Oligodendroglial tumours		
Diffuse astrocytoma, IDH-mutant	II	9400/3
Gemistocytic astrocytoma, IDH-mutant		9411/3
Diffuse astrocytoma, IDH-wildtype		9400/3
Diffuse astrocytoma, NOS		9400/3
Anaplastic astrocytoma, IDH-mutant	III	9401/3
Anaplastic astrocytoma, IDH-wildtype		9401/3
Anaplastic astrocytoma, NOS		9401/3
Glioblastoma, IDH-wildtype		
Giant cell glioblastoma	IV	9440/3
Gliosarcoma		9441/3
Epithelioid glioblastoma		9442/3
Glioblastoma, IDH-mutant	IV	9443/3
Glioblastoma, NOS		9440/3
Diffuse midline glioma, H3 K27M-mutant	IV	9385/3
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted	II	9450/3
Oligodendroglioma, NOS		9450/3
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted	III	9451/3
Anaplastic oligodendroglioma, NOS		9451/3
Oligoastrocytoma, NOS		9382/3
Oligoastrocytoma, NOS		9382/3
Other astrocytic tumours		
Pilocytic astrocytoma	I	9421/1
Pilomyxoid astrocytoma		9425/3
Subependymal giant cell astrocytoma	I	9384/1
Pleomorphic xanthoastrocytoma	II	9424/3
Anaplastic pleomorphic xanthoastrocytoma	III	9424/3

Table. 1 Continued

Tumor class	Grade	ICD-O code
Other gliomas		
Chordoid glioma of the third ventricle	II	9444/1
Angiocentric glioma	I	9431/1
Astroblastoma		9430/3
Neuronal and mixed neuronal-glioma tumours		
Dysembryoplastic neuroepithelial tumour	I	9413/0
Gangliocytoma	I	9492/0
Ganglioglioma	I	9505/1
Anaplastic ganglioglioma	III	9505/3
Dysplastic cerebellar gangliocytoma (Lhermitte-Ducos disease)	I	9493/0
Desmoplastic infantile astrocytoma and ganglioglioma	I	9412/1
Papillary glioneuronal tumour	I	9509/1
Rosette-forming glioneuronal tumour	I	9509/1
Diffuse leptomeningeal glioneuronal tumour		
Central neurocytoma	II	9506/1
Extraventricular neurocytoma	II	9506/1
Cerebellar liponeurocytoma	II	9506/1
Paraganglioma		8693/1

WHO : World Health Organization, ICD-O : the international classification of diseases for oncology, IDH : isocitrate dehydrogenase, NOS : not otherwise specified

the possibility that such an understanding may contribute to the classification of these tumors^{11,42,81}. Accordingly, the inclusion of molecular parameters in the 2016 WHO classification has led to significant changes in the diagnosis of glioma. Diffuse glioma now includes WHO grade II and grade III astrocytic tumors, grade II and III oligodendrogliomas, grade IV glioblastomas, and the related pediatric diffuse gliomas. Accordingly, this approach distinguishes diffuse gliomas from astrocytomas that have a more circumscribed growth pattern, lack IDH gene family alterations, and frequently harbor BRAF alterations (pilocytic astrocytoma, pleomorphic xanthastrocytoma) or TSC1/TSC2 mutations (subependymal giant cell astrocytoma). Accordingly, as diffuse astrocytoma and oligodendrogliomas are now considered nosologically more similar than diffuse astrocytoma and pilocytic astrocytoma, the family trees have been redrawn.

Moreover, despite histological similarities, the molecular characteristics of pediatric gliomas differ greatly from their adult counterparts, both in terms of mutation patterns and the prognostic implications of those mutations. These discoveries include the identification of recurrent mutations, fusion, and

duplication events in the BRAF, FGFR1, MYB, and MYBL1 genes in pediatric low-grade gliomas, as well as mutations affecting histone components (H3F3A p.K27M or p. G34R/V) in pediatric high-grade gliomas^{11,42,73}. Adult low-grade gliomas are characterized by IDH1/2 mutations and ATRX mutations in astrocytic tumors and IDH1/2 mutations and 1p/19q codeletions in oligodendroglial tumors. TERT promoter mutations are also noted in low-grade gliomas and are mainly associated with oligodendrogliomas⁷³.

Second, the concept of pediatric diffuse glioma has evolved. Previously, pediatric diffuse gliomas were grouped with their histologically similar adult counterparts, despite known differences in behavior. The group of tumors that primarily occur in children can be genetically characterized by K27M mutations in the histone H3 gene H3F3A (approximately 75% of cases) or, less commonly, in the related HIST1H3B gene (approximately 25%) and exhibit clinically similar diffuse growth patterns and midline locations (e.g., thalamus, brain stem, and spinal cord). This newly defined entity is termed diffuse midline glioma, H3 K27M-mutant, and includes tumors previously referred to as diffuse intrinsic pontine glioma (DIPG)⁵⁵.

Third, the grading of pilomyxoid astrocytoma has also evolved. In our experience, the pilomyxoid variant always follows a more aggressive course when compared to the suprasellar pilocytic astrocytoma, which has a more classic appearance. Accordingly, a suggestion was made to suppress the grading of pilomyxoid astrocytomas, which would be automatically assigned to WHO grade II until further studies have clarified their behavior.

These advances in pathological diagnosis have led to significant changes in routine clinical practice. For example, tumor genetic profiling has become an essential part of an evaluation. Along with this, the phenotypical and molecular identification of tumors can guide therapies directed against the effects of these mutations. At present, the mainstay of pediatric glioma therapy is surgical treatment, which may be curative for some low-grade gliomas when total resection is possible. However, when total resection is not possible or in cases of high-grade gliomas, the chances for progression or relapse are substantial. Although current adjuvant chemotherapy and radiotherapy are associated with relatively good overall tumor control in low-grade gliomas, they have shown unsatisfactory results for high-grade gliomas. Even for low-grade gliomas, long-term treatment with adjuvant therapy is often associated with significant morbidity¹⁾. Thus, a more tailored and novel approach is needed for pediatric gliomas.

Another interesting discovery is the anatomic distribution of histone mutations in pediatric high-grade gliomas. K27M mutations are predominantly found in tumors arising in midline locations such as the thalamus, pons, and medulla oblongata. Histone H3.3 G34R or G34V mutations and BRAFV600E mutations are predominantly found in hemispheric tumors. Other gene alterations associated with histone gene mutations are also found in location-specific patterns. For example, ATRX/DAXX mutations are associated with cortical G34R/V tumors^{40,81)}. Furthermore, diffuse midline gliomas, H3 K27M-mutant (WHO grade IV) are a distinct group that was introduced in the recent revision of the WHO classification⁵⁵⁾. This group includes the tumors that were previously referred to as DIPG, as well as approximately 50–60% of diffuse gliomas that arise in the thalamus or spinal cord^{75,86)}. Current treatment of these tumors does not include surgical resection due to their challenging location. However, several academic centers around the world have recently incorporated upfront biopsy for the identification of potential molecular alterations for targeted therapy⁶⁹⁾. The surgically inaccessible location of these tumors, along with the fact

that diffuse midline glioma H3 K27M-mutant is less chemosensitive and radiosensitive, results in a poor prognosis for affected children, who have a median survival time of 9–12 months and a survival rate of less than 10% two years after initial diagnosis, regardless of histological grade^{17,43)}. In comparison, children with histone wild-type diffuse midline gliomas show significantly better overall survival times (mean, 4.5 years)⁴³⁾.

Additionally, in patients with NF-1 associated OPGs, there is inactivation of the NF-1 tumor suppressor gene. The NF-1 gene located on chromosome 17q, which encodes neurofibromin, a negative regulator of RAS proto-oncogene³⁰⁾. The NF-1 gene regulates cell differentiation, proliferation, and survival through mitogen activated protein kinase and mammalian target of rapamycin (mTOR) pathways⁴¹⁾. Dysfunction of the NF-1 gene has been found to affect the mTOR pathway promoting cell survival, growth, and proliferation¹⁹⁾. And, it also activates RAS resulting in unregulated cell proliferation⁴⁸⁾. In the case of sporadic OPGs, it demonstrates a rearrangement in the kinase portion of the serine/threonine-protein kinase BRAF gene caused by fusion with KIAA1549 because of a duplication at 7q34 resulting in activation of BRAF^{38,39)}.

Several efforts are underway to develop novel therapeutic approaches for the treatment of pediatric gliomas, but significant challenges remain in translating these insights into clinical practice. Nonetheless, new molecular therapeutics are being evaluated for the treatment of pediatric gliomas, including crizotinib (a MET-fusion target), dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), nimotuzumab (an immunoglobulin G1 antibody that targets EGFR), crenolanib and dasatinib (a PDGFR inhibitor), and bevacizumab (an angiogenesis inhibitor)^{11,40)}. Many clinical trials investigating these targeted agents are still in the early phases, so the outcomes are pending. The success of targeted and personalized therapy not only requires these results, but also continued research into basic signaling mechanisms and the gene regulatory networks that drive the biology of pediatric brain tumors.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

• Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2017R1C1B5018208).

References

1. Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, et al. : Survival and long-term health and cognitive outcomes after low-grade glioma. **Neuro Oncol** **13** : 223-234, 2011
2. Astrup J : Natural history and clinical management of optic pathway glioma. **Br J Neurosurg** **17** : 327-335, 2003
3. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. : Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. **J Clin Oncol** **30** : 2641-2647, 2012
4. Avery RA, Fisher MJ, Liu GT : Optic pathway gliomas. **J Neuroophthalmol** **31** : 269-278, 2011
5. Avery RA, Hwang EI, Jakacki RI, Packer RJ : Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. **JAMA Ophthalmol** **132** : 111-114, 2014
6. Baroncini M, Vinchon M, Minéo JF, Pichon F, Francke JP, Dhellemmes P : Surgical resection of thalamic tumors in children: approaches and clinical results. **Childs Nerv Syst** **23** : 753-760, 2007
7. Bilginer B, Narin F, Işıkay I, Oguz KK, Söylemezoglu F, Akalan N : Thalamic tumors in children. **Childs Nerv Syst** **30** : 1493-1498, 2014
8. Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML : Optic pathway gliomas: a review. **Neurosurg Focus** **23** : E2, 2007
9. Borghei-Razavi H, Shibao S, Schick U : Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome. **Neurosurg Rev** **40** : 135-141, 2017
10. Borja MJ, Plaza MJ, Altman N, Saigal G : Conventional and advanced MRI features of pediatric intracranial tumors: supratentorial tumors. **AJR Am J Roentgenol** **200** : W483-W503, 2013
11. Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D : Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. **J Neurooncol** **134** : 541-549, 2017
12. Broadway SJ, Ogg RJ, Scoggins MA, Sanford R, Patay Z, Boop FA : Surgical management of tumors producing the thalamopeduncular syndrome of childhood. **J Neurosurg Pediatr** **7** : 589-595, 2011
13. Burger PC, Cohen KJ, Rosenblum MK, Tihan T : Pathology of diencephalic astrocytomas. **Pediatr Neurosurg** **32** : 214-219, 2000
14. Cao L, Li C, Zhang Y, Gui S : Surgical resection of unilateral thalamic tumors in adults: approaches and outcomes. **BMC Neurol** **15** : 229, 2015
15. Cappelli C, Grill J, Raquin M, Pierre-Kahn A, Lellouch-Tubiana A, Terrier-Lacombe MJ, et al. : Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. **Arch Dis Child** **79** : 334-338, 1998
16. Cheek WR, Taveras JM : Thalamic tumors. **J Neurosurg** **24** : 505-513, 1966
17. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. : Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. **Neuro Oncol** **13** : 317-323, 2011
18. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J : Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. **Int J Radiat Oncol Biol Phys** **62** : 814-819, 2005
19. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH : Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. **Cancer Res** **65** : 2755-2760, 2005
20. Desai SS, Paulino AC, Mai WY, Teh BS : Radiation-induced moyamoya syndrome. **Int J Radiat Oncol Biol Phys** **65** : 1222-1227, 2006
21. Dodge HW Jr, Love JG, Craig WM, Dockerty MB, Kearns TP, Holman CB, et al. : Gliomas of the optic nerves. **AMA Arch Neurol Psychiatry** **79** : 607-621, 1958
22. El-Shehaby AM, Reda WA, Abdel Karim KM, Emad Eldin RM, Nabeel AM : Single-session Gamma knife radiosurgery for optic pathway/hypothalamic gliomas. **J Neurosurg** **125(1 Suppl)** : 50-57, 2016
23. Finlay JL, Zacharoulis S : The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical-and futuristic-perspective. **J Neurooncol** **75** : 253-266, 2005
24. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. : Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. **Neuro Oncol** **14** : 790-797, 2012
25. Franzini A, Leocata F, Cajola L, Servello D, Allegranza A, Broggi G : Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. **Neurosurgery** **35** : 817-820; discussion 820-821, 1994
26. Goodden JMC : Optic Pathway Hypothalamic Glioma in Winn HR (ed) : **Youmans and Winn Neurological Surgery**, ed 7th. Philadelphia : Elsevier, 2016, pp1660-1667
27. Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G, Marx M, et al. : Radiation therapy of optico-hypothalamic gliomas (OHG)-radiographic response, vision and late toxicity. **Radiother Oncol** **54** : 239-245, 2000
28. Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C, et al. : Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. **Ann Neurol** **45** : 393-396, 1999
29. Gupta A, Shaller N, McFadden KA : Pediatric thalamic gliomas: an updated review. **Arch Pathol Lab Med** **141** : 1316-1323, 2017
30. Gutmann DH, Donahoe J, Brown T, James CD, Perry A : Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. **Neuropathol Appl Neurobiol** **26** : 361-367, 2000

31. Hoffman HJ, Humphreys RP, Drake JM, Rutka JT, Becker LE, Jenkin D, et al. : Optic pathway/hypothalamic gliomas: a dilemma in management. **Pediatr Neurosurg** **19** : 186-195, 1993
32. Hoffman HJ, Soloniuk DS, Humphreys RP, Drake JM, Becker LE, De Lima BO, et al. : Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. **Neurosurgery** **33** : 964-971, 1993
33. Horwich A, Bloom HJ : Optic gliomas: radiation therapy and prognosis. **Int J Radiat Oncol Biol Phys** **11** : 1067-1079, 1985
34. Hoyt WF, Baghdassarian SA : Optic glioma of childhood. Natural history and rationale for conservative management. **Br J Ophthalmol** **53** : 793-798, 1969
35. Hummel TR, Chow LM, Fouladi M, Franz D : Pharmacotherapeutic management of pediatric gliomas: current and upcoming strategies. **Paediatr Drugs** **15** : 29-42, 2013
36. Jahraus CD, Tarbell NJ : Optic pathway gliomas. **Pediatr Blood Cancer** **46** : 586-596, 2006
37. Jeelani ODP : Thalamic Tumors in Winn HR (ed) : **Youmans and Winn Neurological Surgery**, ed 7th. Philadelphia : Elsevier, 2016, pp1669-1676
38. Jones DT, Kocalkowski S, Liu L, Pearson DM, Ichimura K, Collins VP : Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. **Oncogene** **28** : 2119-2123, 2009
39. Jones DT, Kocalkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, et al. : Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. **Cancer Res** **68** : 8673-8677, 2008
40. Juratli TA, Qin N, Cahill DP, Filbin MG : Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. **Pharmacol Ther** **182** : 70-79, 2018
41. Khatua S, Gutmann DH, Packer RJ : Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. **Pediatr Blood Cancer** **65** : 2018
42. Khatua S, Wang J, Rajaram V : Review of low-grade gliomas in children-evolving molecular era and therapeutic insights. **Childs Nerv Syst** **31** : 643-652, 2015
43. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. : K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. **Acta Neuropathol** **124** : 439-447, 2012
44. Komotar RJ, Mocco J, Carson BS, Sughrue ME, Zacharia BE, Sisti AC, et al. : Pilocytic astrocytoma: a review. **MedGenMed** **6** : 42, 2004
45. Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen JJ, et al. : Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. **AJNR Am J Neuroradiol** **22** : 1963-1969, 2001
46. Kramm CM, Butenhoff S, Rausche U, Warmuth-Metz M, Kortmann RD, Pietsch T, et al. : Thalamic high-grade gliomas in children: a distinct clinical subset? **Neuro Oncol** **13** : 680-689, 2011
47. Lambron J, Rakotonjanahary J, Loisel D, Frampas E, De Carli E, Delion M, et al. : Can we improve accuracy and reliability of MRI interpretation in children with optic pathway glioma? Proposal for a reproducible imaging classification. **Neuroradiology** **58** : 197-208, 2016
48. Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH, et al. : Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. **J Neuropathol Exp Neurol** **59** : 759-767, 2000
49. Lee AG : Neuroophthalmological management of optic pathway gliomas. **Neurosurg Focus** **23** : E1, 2007
50. Lee RP, Foster KA, Lillard JC, Klimo P Jr, Ellison DW, Orr B, et al. : Surgical and molecular considerations in the treatment of pediatric thalamoponduncular tumors. **J Neurosurg Pediatr** **20** : 247-255, 2017
51. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D : Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. **Int J Radiat Oncol Biol Phys** **95** : 267-278, 2016
52. Listernick R, Ferner RE, Liu GT, Gutmann DH : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. **Ann Neurol** **61** : 189-198, 2007
53. Listernick R, Louis DN, Packer RJ, Gutmann DH : Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. **Ann Neurol** **41** : 143-149, 1997
54. Liu GT : Optic gliomas of the anterior visual pathway. **Curr Opin Ophthalmol** **17** : 427-431, 2006
55. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 world health organization classification of tumors of the central nervous system: a summary. **Acta Neuropathol** **131** : 803-820, 2016
56. Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, et al. : MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. **AJNR Am J Neuroradiol** **26** : 777-783, 2005
57. Massimi L, Tufo T, Di Rocco C : Management of optic-hypothalamic gliomas in children: still a challenging problem. **Expert Rev Anticancer Ther** **7** : 1591-1610, 2007
58. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S : Does chemotherapy affect the visual outcome in children with optic pathway glioma? a systematic review of the evidence. **Eur J Cancer** **46** : 2253-2259, 2010
59. Opocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN, et al. : Prognostic factors for progression of childhood optic pathway glioma: a systematic review. **Eur J Cancer** **42** : 1807-1816, 2006
60. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. : CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. **Neuro Oncol** **18** : v1-v75, 2016
61. Ozek MM, Türe U : Surgical approach to thalamic tumors. **Childs Nerv Syst** **18** : 450-456, 2002
62. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. : Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. **J Neurosurg** **86** : 747-754, 1997
63. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. : Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. **J Clin Oncol** **11** : 850-856, 1993

64. Panigrahy A, Blüml S : Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). **J Child Neurol** **24** : 1343-1365, 2009
65. Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, et al. : Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging. **Arch Ophthalmol** **119** : 516-529, 2001
66. Pollack IF, Claassen D, al-Shboul Q, Janosky JE, Deutsch M : Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. **J Neurosurg** **82** : 536-547, 1995
67. Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, et al. : The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. **J Pediatr** **167** : 851-856.e1, 2015
68. Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA : Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. **J Neurooncol** **32** : 235-241, 1997
69. Puget S, Beccaria K, Blauwblomme T, Roujeau T, James S, Grill J, et al. : Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. **Childs Nerv Syst** **31** : 1773-1780, 2015
70. Puget S, Crimmins DW, Garnett MR, Grill J, Oliveira R, Boddaert N, et al. : Thalamic tumors in children: a reappraisal. **J Neurosurg** **106** : 354-362, 2007
71. Pungavkar SA, Lawande MA, Patkar DP, Agrawal NV, Gadani S : Bilateral optic pathway glioma with intracranial calcification: magnetic resonance imaging and magnetic resonance spectroscopy findings. **Australas Radiol** **49** : 489-492, 2005
72. Rasool N, Odel JG, Kazim M : Optic pathway glioma of childhood. **Curr Opin Ophthalmol** **28** : 289-295, 2017
73. Rodriguez FJ, Vizcaino MA, Lin MT : Recent advances on the molecular pathology of glial neoplasms in children and adults. **J Mol Diagn** **18** : 620-634, 2016
74. Sai Kiran NA, Thakar S, Dadlani R, Mohan D, Furtado SV, Ghosal N, et al. : Surgical management of thalamic gliomas: case selection, technical considerations, and review of literature. **Neurosurg Rev** **36** : 383-393, 2013
75. Schwartzenuber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. : Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. **Nature** **482** : 226-231, 2012
76. Shapely J, Danesh-Meyer HV, Kaye AH : Diagnosis and management of optic nerve glioma. **J Clin Neurosci** **18** : 1585-1591, 2011
77. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. **J Clin Oncol** **24** : 2570-2575, 2006
78. Shen TT, Sakai O, Curtin HD, Rizzo JF 3rd : Magnetic resonance imaging of primary anterior visual pathway tumors. **Int Ophthalmol Clin** **41** : 171-180, 2001
79. Steinbok P, Gopalakrishnan CV, Hengel AR, Vitali AM, Poskitt K, Hawkins C, et al. : Pediatric thalamic tumors in the MRI era: a Canadian perspective. **Childs Nerv Syst** **32** : 269-280, 2016
80. Stieber VW : Radiation therapy for visual pathway tumors. **J Neuroophthalmol** **28** : 222-230, 2008
81. Sturm D, Pfister SM, Jones DTW : Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. **J Clin Oncol** **35** : 2370-2377, 2017
82. Suárez JC, Viano JC, Zunino S, Herrera EJ, Gomez J, Tramunt B, et al. : Management of child optic pathway gliomas: new therapeutical option. **Childs Nerv Syst** **22** : 679-684, 2006
83. Sylvester CL, Drohan LA, Sergott RC : Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. **Curr Opin Ophthalmol** **17** : 7-11, 2006
84. Wisoff JH, Abbott R, Epstein F : Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. **J Neurosurg** **73** : 661-667, 1990
85. Wong TT, Chen HH, Liang ML, Hsieh KL, Yang YS, Ho DM, et al. : Clinical considerations and surgical approaches for low-grade gliomas in deep hemispheric locations: thalamic lesions. **Childs Nerv Syst** **32** : 1895-1906, 2016
86. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Beckwith J, et al. : Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. **Nat Genet** **44** : 251-253, 2012
87. Yeom KW, Lober RM, Andre JB, Fisher PG, Barnes PD, Edwards MS, et al. : Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma. **J Neurooncol** **113** : 479-483, 2013